imugene (asx: imu) – first patient dosed in checkvacc phase 1 trials
Published 2 years ago • 2.9K plays • Length 9:34Download video MP4
Download video MP3
Similar videos
-
6:40
imugene doses first patient in vaxinia phase 1 trial
-
4:00
first patient dosed in imugene's pd1-vaxx combination trial
-
4:14
imugene (asx:imu) doses first patient in iv arm of phase 1 oncarlytics trial targeting solid cancers
-
2:30
imugene thrilled as first patient dosed in phase 1 oasis trial
-
5:00
imugene doses first patient in intravenous monotherapy arm of phase 1 clinical trial
-
5:15
imugene | first patients dosed in vaxinia mast combination study
-
5:00
imugene doses first patient in intravenous monotherapy arm of phase 1 clinical trial
-
4:14
imugene doses first patient in phase 1 oncarlytics iv infusion combination trial
-
19:03
imugene steps up dosage at groundbreaking vaxinia cancer trial
-
5:04
imugene (asx:imu) | jmm & éthica capital innovation interview \ may 2024
-
4:45
first cohort 3 patient dosed in checkvacc trial
-
6:43
imugene's leslie chong welcomes first patient dosed in checkvacc trial
-
6:29
imugene finishes phase 1a monotherapy dose escalation of pd1 vaxx
-
26:23
imugene (asx:imu) presentation, nwr virtual healthcare conference
-
20:57
imugene (asx: imu) - discussing imu's 2022 biotech opportunity
-
18:08
asx/ausbiz biotech unlocked with imugene ceo leslie chong
-
5:20
imugene welcomes dosing of first patient in nextherizon phase 2 clinical trial
-
10:00
imugene begins vaxinia trial for bile tract cancer
-
8:59
imugene officially announce their her-vaxx trial results